The UK says it will recognize EU centralized marketing authorization (MA) decisions for two years in Great Britain after the Brexit transition period ends on 31 December this year, subject to “a risk-based review” that takes account of any GB-specific conditions.
The medicines regulator, the MHRA, has also confirmed that its new accelerated assessment procedure will produce a decision on approval in just 150 days, and will apply to products containing